Share this article on:

A new role of growth hormone and insulin-like growth factor receptor type 1 in neonatal inflammatory nociception: response to commentary

Jankowski, Michael P.a,b,*

doi: 10.1097/PR9.0000000000000609
Journal Club

aDepartment of Anesthesia, Division of Pain Management, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

bDepartment of Pediatrics, University of Cincinnati, Cincinnati, OH, USA

Corresponding author. Address: Department of Anesthesia, Division of Pain Management, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave MLC 6016, Cincinnati, OH 45229. Tel.: (513) 803-7966. E-mail address: michael.jankowski@cchmc.org (M.P. Jankowski).

The author has no conflicts of interest to declare.

This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0 (CC BY-ND) which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.

Received May 19, 2017

Accepted May 24, 2017

See commentary: Manzano-Garcia A, Gamal-Eltrabily M. A new role of growth hormone and insulin growth factor receptor type 1 in neonatalinflammatory nociception. PAIN Reports 2017:e608.

The authors provide a nice summary of our recent report on how growth hormone (GH) regulates neonatal inflammatory pain. We still need to understand how GH is downregulated during peripheral injury and how this reduction causes a paradoxical increase in sensory neuron IGFr1. To clarify, IGF-1 was not statistically increased in the skin as suggested. Furthermore, although not confirmed in vivo, in vitro data suggest direct effects of GH on neuronal IGFr1 expression. Nevertheless, this article highlights the next logical steps we are currently pursuing to elucidate mechanisms by which GH may provide neonatal analgesia.

© 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The International Association for the Study of Pain.